For the first time in over two decades, patients at King's College Hospital have received life-saving plasma medicines made entirely from UK donations – marking a pivotal moment in Britain's journey towards healthcare independence. This milestone represents years of careful planning and investment to reduce our reliance on imported treatments that thousands of patients depend upon for survival.
The treatments, called immunoglobulins, are derived from human plasma and provide crucial antibodies to patients whose immune systems cannot protect them adequately. These medicines are essential for people with primary immunodeficiencies – conditions where the body struggles to fight infections naturally. Until now, the UK has depended almost entirely on imported plasma to manufacture these treatments, creating potential vulnerabilities in our supply chain.
This breakthrough follows the lifting of a 25-year ban on using UK plasma for medicine production. The restriction was introduced in 1998 due to concerns about variant Creutzfeldt-Jakob disease (vCJD), but was lifted by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2021 following extensive safety reviews. The decision came after rigorous assessment of donor screening processes and safety protocols.
Since the programme launched in 2021, NHS Blood and Transplant (NHSBT) has collected over 350,000 plasma donations. These donations undergo specialist processing to create the medicines that patients desperately need. The first doses administered at King's College Hospital represent the culmination of this major national effort to rebuild our domestic medicine supply.
For patients requiring these treatments – often for life – this development promises greater security and stability. Many people with conditions like common variable immunodeficiency, multifocal motor neuropathy, and Kawasaki disease require regular immunoglobulin infusions. Having a UK supply reduces risks from global market fluctuations, geopolitical tensions, and economic pressures that can affect medicine availability and costs.
This initiative forms part of the NHS's broader strategy to strengthen healthcare resilience whilst maintaining the highest standards of patient care. The long-term aim is to substantially increase the proportion of plasma medicines sourced from UK donations, enhancing our national health security and potentially improving treatment access for vulnerable patients across the country.